FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease

FibroGen (FGEN) Misses Q3 EPS by 2c, Revenues Miss

November 11, 2019 4:04 PM EST

FibroGen (NASDAQ: FGEN) reported Q3 EPS of ($0.57), $0.02 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $33.17 million versus the consensus estimate of $31.6 million.

The FibroGen team achieved many milestones over the past few months, culminating with the positive Phase 3 results for roxadustat reported at the American Society of Nephrology conference last week in Washington, D.C., said Jim Schoeneck, Interim Chief Executive Officer, FibroGen. This set... More

FibroGen (FGEN) to Resume Trading at 2:30 pm

November 8, 2019 2:12 PM EST

FibroGen (NASDAQ: FGEN) to Resume Trading at 2:30 pm

... More